{"id":54,"date":"2013-02-04T14:25:34","date_gmt":"2013-02-04T19:25:34","guid":{"rendered":"http:\/\/licensinglaw.net\/blog3\/?page_id=54"},"modified":"2021-04-12T08:39:21","modified_gmt":"2021-04-12T12:39:21","slug":"nces-treatment-methods","status":"publish","type":"page","link":"https:\/\/licensinglaw.net\/blog3\/?page_id=54","title":{"rendered":"Extending Patent Term"},"content":{"rendered":"<p style=\"text-align: justify;\">For clinical-stage products, a carefully-managed appeal can provide an interesting venue for product life cycle management, moving years of patent term from the clinical stage of the product life cycle (where patent protection is usually not needed) to the post-approval commercial stage of the product life cycle (where patent protection may be critical).\u00a0 Might extended patent term be a valuable addition to your clinical-stage products?\u00a0 If so, Contact Us.\u00a0 A leading pharmacognosy research and development company did, and here is what happened:<\/p>\n<p style=\"text-align: justify;\"><a href=\"http:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/interferon_efficacy1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-thumbnail wp-image-295\" src=\"http:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/interferon_efficacy1-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/interferon_efficacy1-150x150.jpg 150w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/interferon_efficacy1-432x432.jpg 432w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/interferon_efficacy1-268x268.jpg 268w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/a>HP Ingredients developed a pharmacognosy-derived, small-molecule new chemical entity useful to treat rheumatoid arthritis.\u00a0 When the Examiner rejected the claims, we filed an appeal to the Board.\u00a0 The Examiner&#8217;s SPE found our Appeal Brief cogent enough to require the Examiner to withdraw her rejections.<\/p>\n<p style=\"text-align: justify;\">When the Examiner rejected the claims again, we filed a second appeal.\u00a0 This time, the Board found our appeal brief cogent enough to\u00a0 require the Examiner to withdraw her rejections.<\/p>\n<p style=\"text-align: justify;\">These repeated appeals ultimately convinced the Examiner to allow the case (<a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=793\">US8084495<\/a>).\u00a0 The appeals also provided a valuable commercial benefit: by forcing the Examiner to repeatedly concede that her rejections were not sustainable, the resulting patent won a patent term extension of <em>nearly 4 \u00bd years<\/em>.\u00a0\u00a0 This extension was important commercially, because it took nearly 4 \u00bd years of patent protection and moved it from the clinical stage (where patent protection is not needed) to the future, post-approval commercial stage (where patent protection is critical).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For clinical-stage products, a carefully-managed appeal can provide an interesting venue for product life cycle management, moving years of patent term from the clinical stage of the product life cycle (where patent protection is usually not needed) to the post-approval commercial stage of the product life cycle (where patent protection &#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":17,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"template-full-width.php","meta":{"footnotes":""},"class_list":["post-54","page","type-page","status-publish","hentry","column","twocol"],"_links":{"self":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/54","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54"}],"version-history":[{"count":13,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/54\/revisions"}],"predecessor-version":[{"id":795,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/54\/revisions\/795"}],"up":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/17"}],"wp:attachment":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}